Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | More
or

Kezar Life Sciences Inc (KZR)

Kezar Life Sciences Inc (KZR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 46,811
  • Shares Outstanding, K 72,801
  • Annual Sales, $ 7,000 K
  • Annual Income, $ -101,870 K
  • 60-Month Beta 0.28
  • Price/Sales 7.06
  • Price/Cash Flow N/A
  • Price/Book 0.29
Trade KZR with:
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -1.32
  • Most Recent Earnings $-0.30 on 05/09/24
  • Next Earnings Date 08/08/24
  • Annual Dividend & Yield N/A (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sectors:

Options Overview Details

View History
  • Implied Volatility 482.15% ( -176.01%)
  • Historical Volatility 52.56%
  • IV Percentile 85%
  • IV Rank 56.96%
  • IV High 812.53% on 03/27/24
  • IV Low 44.88% on 07/19/23
  • Put/Call Vol Ratio 0.00
  • Today's Volume 30
  • Volume Avg (30-Day) 15
  • Put/Call OI Ratio 0.01
  • Today's Open Interest 1,232
  • Open Int (30-Day) 1,251

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 5 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/24
See More
  • Average Estimate -0.32
  • Number of Estimates 4
  • High Estimate -0.26
  • Low Estimate -0.36
  • Prior Year -0.34
  • Growth Rate Est. (year over year) +5.88%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.5380 +20.84%
on 07/02/24
0.7040 -7.66%
on 07/17/24
-0.0048 (-0.73%)
since 06/18/24
3-Month
0.5380 +20.84%
on 07/02/24
0.8679 -25.10%
on 05/02/24
-0.1399 (-17.71%)
since 04/19/24
52-Week
0.5380 +20.84%
on 07/02/24
2.5500 -74.51%
on 07/21/23
-1.7399 (-72.80%)
since 07/19/23

Most Recent Stories

More News
Karora Announces Agreement with Kalamazoo Resources to Unlock Lithium Exploration Value Through Creation of Kali Metals Limited

/CNW/ - Karora Resources Inc. (TSX: KRR) ("Karora" or the "Corporation") is pleased to announce it has entered into an agreement with Kalamazoo Resources...

KZR.AX : 0.078 (-2.50%)
KZR : 0.6501 (+1.10%)
KRR.TO : 6.89 (+0.58%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.6501 (+1.10%)
Kezar Life Sciences Reports Fourth Quarter and Year End 2022 Financial Results and Provides Business Update

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune mediated and oncologic disorders, today reported financial...

KZR : 0.6501 (+1.10%)
Kezar Life Sciences to Change Virtual R&D Day Date to March 15, 2023

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that the...

KZR : 0.6501 (+1.10%)
Kezar Life Sciences to Host Virtual R&D Day on March 22, 2023

Kezar Life Sciences, Inc. (Nasdaq: KZR), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that it will...

KZR : 0.6501 (+1.10%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.6501 (+1.10%)
Kezar Life Sciences to Participate in the Cowen 43rd Annual Health Care Conference

Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that Noreen...

KZR : 0.6501 (+1.10%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.6501 (+1.10%)
Kezar Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Kezar Life Sciences, Inc ., (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that...

KZR : 0.6501 (+1.10%)
Kezar Life Sciences to Present at the 41st Annual J.P. Morgan Healthcare Conference

Kezar Life Sciences, Inc . (Nasdaq: KZR ), a clinical-stage biotechnology company discovering and developing breakthrough treatments for immune-mediated and oncologic disorders, today announced that John...

KZR : 0.6501 (+1.10%)

Business Summary

Kezar Life Sciences, Inc. is a bio-technology company. It discovers and develops molecule therapeutics and medicines such as protein homeostasis for autoimmune disorders. The company's product pipeline consists of KZR-616 which is in clinical stage. Kezar Life Sciences, Inc. is headquartered in South...

See More

Key Turning Points

3rd Resistance Point 0.7419
2nd Resistance Point 0.7209
1st Resistance Point 0.6820
Last Price 0.6501
1st Support Level 0.6221
2nd Support Level 0.6011
3rd Support Level 0.5622

See More

52-Week High 2.5500
Fibonacci 61.8% 1.7814
Fibonacci 50% 1.5440
Fibonacci 38.2% 1.3066
Last Price 0.6501
52-Week Low 0.5380

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.

Free Barchart Webinar